ARCUTIS BIOTHERAPEUTICS, INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $1.63 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-12-31 was $1.06M, a 0.66% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2025-09-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-12-31 was $1.06M, a 484.62% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2024-09-30 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2025 was $2.38M, a 38.70% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2024 was $1.71M, a 45.79% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $1.18M, a 38.87% decline from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $1.92M, a 128.27% increase from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.63M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.06M derived: sum of 2 quarters · filed 2026-02-25 | $2.38M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.32M 10-Q · filed 2025-10-28 | ||
| 2025-06-30 | $1.32M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.06M derived: sum of 2 quarters · filed 2026-02-25 | $1.71M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $649.00K 10-Q · filed 2025-10-28 | ||
| 2024-06-30 | $649.00K 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $182.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.18M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $993.00K 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $993.00K 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $946.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.92M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $976.00K 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $976.00K 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $364.00K derived: sum of 2 quarters · filed 2024-02-27 | $842.00K 10-K · filed 2024-02-27 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $478.00K 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $478.00K 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $330.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $330.00K derived: sum of 2 quarters · filed 2023-02-28 | $617.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $287.00K 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $287.00K 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $0.00 derived: sum of 2 quarters · filed 2022-02-22 | $0.00 10-K · filed 2022-02-22 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-11 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |